Release

Today’s Research Reports on Novadaq Technologies, Aralez Pharmaceuticals, Neptune Technologies & Bioressources and Trillium Therapeutics

Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://rdinvesting.com and get exclusive access to our numerous research reports and market updates.

RDI Initiates Coverage on:

Novadaq Technologies Inc.
https://ub.rdinvesting.com/news/?ticker=NDQ-TO

Aralez Pharmaceuticals Inc.
https://ub.rdinvesting.com/news/?ticker=ARZ-TO

Neptune Technologies & Bioressources Inc.
https://ub.rdinvesting.com/news/?ticker=NEPT-TO

Trillium Therapeutics Inc.
https://ub.rdinvesting.com/news/?ticker=TRIL-TO

Novadaq Technologies Inc.’s stock edged 0.20% lower Thursday, to close the day at $15.26. The stock recorded a trading volume of 9,966 shares, which was below its three months average volume of 10,848 shares. In the last year Novadaq Technologies Inc.’s shares have traded in a range of 7.81 – 16.42. The share price has gained 95.39% from its 52 week low. The company’s shares are currently trading above their 200-day moving average. Moreover, the stock’s 50-day moving average of $10.98 is greater than its 200-day moving average of $9.96. Shares of Novadaq Technologies have gained approximately 65.3 percent year-to-date.

Access RDI’s Novadaq Technologies Research Report at:
https://ub.rdinvesting.com/news/?ticker=NDQ-TO

On Thursday, shares in Aralez Pharmaceuticals Inc. recorded a trading volume of 33,391 shares, which was below the three months average volume of 54,903 shares. The stock ended the day 0.57% higher at 1.77. The share price has gained 21.23% from its 52 week low with a 52 week trading range of 1.46 – 8.75.The company’s shares are currently trading below their 200-day moving average. Moreover, the stock’s 50-day moving average of $1.78 is below its 200-day moving average of $3.73. Shares of Aralez Pharmaceuticals have fallen approximately 70.05 percent year-to-date.

Access RDI’s Aralez Pharmaceuticals Research Report at:
https://ub.rdinvesting.com/news/?ticker=ARZ-TO

Neptune Technologies & Bioressources Inc.’s stock edged 0.90% lower Thursday, to close the day at $1.10. The stock recorded a trading volume of 23,950 shares, which was below its three months average volume of 43,192 shares. In the last year Neptune Technologies & Bioressources Inc.’s shares have traded in a range of 1.07 – 2.02. The stock is currently trading 45.54% below its 52 week high. The company’s shares are currently trading below their 200-day moving average. Moreover, the stock’s 50-day moving average of $1.33 is below its 200-day moving average of $1.35. Shares of Neptune Technologies & Bioressources Inc. are trading at a Price to Earnings ratio of 13.41. Shares of Neptune Technologies & Bioressources have fallen approximately 15.38 percent year-to-date.

Access RDI’s Neptune Technologies & Bioressources Research Report at:
https://ub.rdinvesting.com/news/?ticker=NEPT-TO

On Thursday, shares in Trillium Therapeutics Inc. recorded a trading volume of 1,335 shares, which was below the three months average volume of 5,645 shares. The stock ended the day 2.43% lower at 5.61. The stock is currently trading 76.11% below its 52 week high with a 52 week trading range of 5.60 – 23.48.The company’s shares are currently trading below their 200-day moving average. Moreover, the stock’s 50-day moving average of $6.76 is below its 200-day moving average of $7.62. Shares of Trillium Therapeutics have fallen approximately 26.28 percent year-to-date.

Access RDI’s Trillium Therapeutics Research Report at:
https://ub.rdinvesting.com/news/?ticker=TRIL-TO

Our Actionable Research on Novadaq Technologies Inc. (TSX:NDQ), Aralez Pharmaceuticals Inc. (TSX:ARZ), Neptune Technologies & Bioressources Inc. (TSX:NEPT) and Trillium Therapeutics Inc. (TSX:TRIL) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

[email protected]

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.